See more : ESGEN Acquisition Corporation (ESACU) Income Statement Analysis – Financial Results
Complete financial analysis of Creo Medical Limited (CREO.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Creo Medical Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- Komipharm International Co., Ltd. (041960.KQ) Income Statement Analysis – Financial Results
- Wallenstam AB (publ) (WALL-B.ST) Income Statement Analysis – Financial Results
- IOL Chemicals and Pharmaceuticals Limited (IOLCP.BO) Income Statement Analysis – Financial Results
- Winix Inc. (044340.KQ) Income Statement Analysis – Financial Results
- Hiday Hidaka Corp. (7611.T) Income Statement Analysis – Financial Results
Creo Medical Limited (CREO.L)
About Creo Medical Limited
Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 30.80M | 27.17M | 25.16M | 9.43M | 13.47K | 0.00 | 0.00 | 0.00 | 534.67K | 0.00 | 802.48K |
Cost of Revenue | 15.50M | 17.16M | 16.14M | 6.99M | 650.25K | 331.61K | 0.00 | 142.42K | 103.52K | 74.41K | 0.00 |
Gross Profit | 15.30M | 10.01M | 9.02M | 2.44M | -636.77K | -331.61K | 0.00 | -142.42K | 431.16K | -74.41K | 802.48K |
Gross Profit Ratio | 49.68% | 36.84% | 35.86% | 25.86% | -4,726.29% | 0.00% | 0.00% | 0.00% | 80.64% | 0.00% | 100.00% |
Research & Development | 0.00 | 13.53M | 12.87M | 10.19M | 8.15M | 5.23M | 0.00 | 3.58M | 2.50M | 0.00 | 0.00 |
General & Administrative | 40.50M | 43.93M | 41.54M | 27.57M | 19.01M | 11.96M | 10.51M | 9.18M | 4.34M | 2.88M | 2.75M |
Selling & Marketing | 0.00 | -16.64M | -15.43M | -11.93M | -8.77M | -5.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 40.50M | 27.29M | 26.11M | 15.64M | 10.24M | 6.38M | 10.51M | 9.18M | 4.34M | 2.88M | 2.75M |
Other Expenses | -400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -225.00K | -277.69K | -534.67K | 0.00 | -802.48K |
Operating Expenses | 40.10M | 40.82M | 38.98M | 25.83M | 18.38M | 11.61M | 10.29M | 8.90M | 3.80M | 2.88M | 1.95M |
Cost & Expenses | 55.60M | 57.98M | 55.12M | 32.82M | 19.03M | 11.94M | 10.29M | 8.90M | 3.80M | 2.88M | 1.95M |
Interest Income | 700.00K | 34.00K | 31.00K | 178.00K | 311.29K | 62.32K | 7.89K | 5.34K | 5.79K | 2.41K | 263.00 |
Interest Expense | 400.00K | 248.00K | 237.00K | 97.00K | 14.07K | 11.16K | 7.60K | 10.72K | 2.57K | 0.00 | 4.00 |
Depreciation & Amortization | 3.40M | 3.11M | 2.56M | 1.60M | 641.72K | 331.61K | 309.72K | 142.42K | 103.52K | 74.41K | 61.90K |
EBITDA | -20.70M | -27.62M | -27.54M | -21.77M | -17.96M | -11.37M | -9.97M | -8.76M | -3.70M | -2.81M | -1.89M |
EBITDA Ratio | -67.21% | -101.93% | -108.89% | -231.15% | -136,395.23% | 0.00% | 0.00% | 0.00% | -690.65% | 0.00% | -235.47% |
Operating Income | -24.80M | -30.81M | -29.96M | -23.39M | -19.02M | -11.94M | -10.29M | -8.90M | -3.80M | -2.88M | -1.95M |
Operating Income Ratio | -80.52% | -113.39% | -119.07% | -248.09% | -141,158.24% | 0.00% | 0.00% | 0.00% | -711.10% | 0.00% | -243.22% |
Total Other Income/Expenses | 300.00K | -200.00K | -380.00K | -70.00K | 260.00K | 224.58K | 287.00 | -5.38K | 4.23K | 2.80K | 259.00 |
Income Before Tax | -24.50M | -30.98M | -30.34M | -23.46M | -18.62M | -11.72M | -10.29M | -8.91M | -3.80M | -2.88M | -1.95M |
Income Before Tax Ratio | -79.55% | -114.02% | -120.58% | -248.83% | -138,168.05% | 0.00% | 0.00% | 0.00% | -710.30% | 0.00% | -243.19% |
Income Tax Expense | -2.80M | -4.04M | -5.74M | -3.15M | -2.70M | -1.85M | -1.88M | -1.14M | -468.19K | -496.19K | -254.87K |
Net Income | -21.70M | -26.94M | -24.60M | -20.32M | -15.91M | -9.87M | -8.41M | -7.77M | -3.33M | -2.38M | -1.70M |
Net Income Ratio | -70.45% | -99.14% | -97.75% | -215.46% | -118,096.56% | 0.00% | 0.00% | 0.00% | -622.74% | 0.00% | -211.43% |
EPS | -0.07 | -0.14 | -0.14 | -0.13 | -0.13 | -0.11 | -0.10 | -0.13 | -0.04 | -0.03 | -0.02 |
EPS Diluted | -0.07 | -0.14 | -0.14 | -0.13 | -0.13 | -0.11 | -0.10 | -0.12 | -0.04 | -0.03 | -0.02 |
Weighted Avg Shares Out | 313.00M | 187.89M | 170.38M | 161.58M | 125.84M | 93.78M | 83.92M | 60.02M | 83.74M | 83.74M | 83.74M |
Weighted Avg Shares Out (Dil) | 313.00M | 187.89M | 170.38M | 161.58M | 125.84M | 93.78M | 83.92M | 62.27M | 83.74M | 83.74M | 83.74M |
Source: https://incomestatements.info
Category: Stock Reports